Study of Volrustomig as Monotherapy or in Combination with Anti- cancer Agents in Participants with Advanced/Metastatic Solid Tumors

Trial Identifier: D798MC00002
Sponsor: AstraZeneca
Start Date: August 2024
Primary Completion Date: July 2026
Study Completion Date: July 2026
Condition: Cancer - Other

Available Languages

For questions about your Trial Results Summary, please see Sponsor contact section within your Trial Results Summary.

No documents have been posted yet.

Trial Locations

Country Location
CN Beijing, CN, CN-100730
CN Beijing, CN, 100730
CN Beijing, CN, 100142
CN Bengbu, CN, 233060
CN Changchun, CN, 130021
CN Changsha, CN, 410008
CN Changsha, CN, 410013
CN Chengdu, CN, 610041
CN Chongqing, CN, 400030
CN Dongguan, CN, 523009
CN fuzhou, CN, 350011
CN Hangzhou, CN, 310022
CN Jining, CN, 272029
CN Kunming, CN, 650118
CN Nanchang, CN, 330006
CN Nanning, CN, 530021
CN Shandong, CN
CN Shanghai, CN, 200120
CN Shenyang, CN, 110004
CN Tianjin, CN, 300060
CN Wuhan, CN, 430022
CN Wuhan, CN, 430079